[1] Pustjens, T.F.S., Appelman, Y., Damman, P. et al. Guidelines for the management of myocardial infarction/injury with non-obstructive coronary arteries (MINOCA): a position paper from the Dutch ACS working group. Neth Heart J (2019). https://doi.org/10.1007/s12471-019-01344-6
[2] Collste O, Sorensson P, Frick M, et al. Myocardial infarction with normal coronary arteries is common and associated with normal findings on cardiovascular magnetic resonance imaging: results from the Stockholm MyocardialInfarction with Normal Coronaries study. J Intern Med.2013;273(2):189–96.
[3] Pasupathy S, Tavella R, Beltrame JF. Myocardial infarction with Nonobstructive coronary arteries (MINOCA):the past, present ,and future management.Circulation.2017;135(16):1490–3
[4] Ezra A. Amsterdam, Nanette K. Wenger, Ralph G. Brindis, Donald E. Casey, Theodore G. Ganiats, David R. Holmes, Allan S. Jaffe, Hani Jneid, Rosemary F. Kelly, Michael C. Kontos, Glenn N. Levine, Philip R. Liebson, Debabrata Mukherjee, Eric D. Peterson, Marc S. Sabatine, Richard W. Smalling, Susan J. Zieman. J Am Coll Cardiol. 2014 Dec, 64 (24) e139-e228.
[5] Roe M T, Harrington R A, Prosper D M, etal. Clinical and therapeutic profile of patients presenting with acute coronarySyndromes who do not have significant coronary artery disease. The Platelet Glycoprotein IIb/IIIa in Unstable Angina:Receptor Suppression Using Integril in Therapy (PURSUIT) trial investigators. Circulation. 2000;102(10):1101–6
[6] Safdar B, Spatz ES, Dreyer RP, et al. Presentation, clinical profile, and prognosis of young patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): results from the VIRGO study. J Am Heart Assoc. 2018; https://doi.org/10.1161/JAHA.118.009174.
[7] Larsen AI, Nilsen DW, Yu J, et al. Long-term prognosis of patients presenting with ST-segment elevation myocardial infarction with no significant coronary artery disease (from the HORIZONS-AMI trial). Am J Cardiol. 2013;111(5):643–8
[8] Patel MR, Chen AY, Peterson ED, et al. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE)initiative. AmHeartJ.2006;152(4):641–7.
[9] Vasile V., Jaffe A. High-Sensitivity Cardiac Troponin in the Evaluation of Possible AMI. American College of Cardiology. Expert Analysis. July 2018. Retrieved 24th September 2020.
[10] Collet J., Thiele H., Barbato E., et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients with persistent ST-segment elevation. European Heart Journal (2020) 00, 179. doi:10.1093/eurheartj/ehaa575
[11]Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina) J Am Coll Cardiol. 2002;40:1366–1374.
[12] Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969.
[13] Mandrekar J. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010; 5(9):1315-1316. doi: 10.1097/JTO.0b013e3181ec173d.
[14] Korff S., Katus H., Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006; 92:987–993. doi: 10.1136/hrt.2005.071282
[15] Kanjwal, K., Imran, N., Grubb, B., &Kanjwal, Y. (2008). Troponin elevation in patients with various tachycardias and normal epicardial coronaries. Indian pacing and electrophysiology journal, 8(3), 172–174.
[16] Kelley W, Januzzi J, Christenson R. Increases of Cardiac Troponin in Conditions other than Acute Coronary Syndrome and Heart Failure. Clinical Chemistry. 2009; 55(12): 2098–2112.
[17] Ralli S, Horwich TB, Fonarow GC. Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J. 2005;150(6):1220-1227.
[18] Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Kaikkonen K, Haataja P, Kerola T, Kupari M. Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis. Am J Cardiol2015;116:960–964.